These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 5560686)

  • 1. Inhibition of L-Phenylalanine absorption by L-DOPA in patients with parkinsonism.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Proc Soc Exp Biol Med; 1971 Jul; 137(3):942-4. PubMed ID: 5560686
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of L-dopa on seborrhoea of parkinsonism.
    Burton JL; Shuster S
    Lancet; 1970 Jul; 2(7662):19-20. PubMed ID: 4193751
    [No Abstract]   [Full Text] [Related]  

  • 3. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of L-dopa on seborrhoea of parkinsonism.
    Wyburn-Mason R
    Lancet; 1970 Jul; 2(7664):154. PubMed ID: 4194540
    [No Abstract]   [Full Text] [Related]  

  • 5. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenylalanine absorption and metabolism in Parkinsonian patients.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Br Med J; 1971 Oct; 4(5782):262-4. PubMed ID: 5123908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinsonism, L-dopa, and intelligence.
    Loranger AW; Goodell H; McDowell FH; Lee JE; Sweet RD
    Am J Psychiatry; 1973 Dec; 130(12):1386-9. PubMed ID: 4754685
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral phenylalanine and tyrosine tolerance tests in Parkinsonian patients.
    Braham J; Sarova-Pinhas I; Crispin M; Golan R; Levin N; Szeinberg A
    Br Med J; 1969 May; 2(5656):552-5. PubMed ID: 5769891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sexual behavior during L-dopa treatment for Parkinsonism.
    Bowers MB; Van Woert M; Davis L
    Am J Psychiatry; 1971 Jun; 127(12):1691-3. PubMed ID: 5565858
    [No Abstract]   [Full Text] [Related]  

  • 10. The reciprocal exclusion by L-dopa (L-3,4-dihydroxyphenylalanine) and L-tyrosine of their incorporation as single units into a soluble rat brain protein.
    Rodriguez JA; Barra HS; Arce CA; Hallak ME; Caputto R
    Biochem J; 1975 Jul; 149(1):115-21. PubMed ID: 1191253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Theray of Parkinson-syndrome with Helfo-Dopa].
    Roeder F
    Med Klin; 1970 Nov; 65(45):1983-7. PubMed ID: 5520307
    [No Abstract]   [Full Text] [Related]  

  • 12. [L-dopa in the treatment of Parkinsonism].
    Domzal T; Pakszys W
    Wiad Lek; 1972 Aug; 25(15):1391-5. PubMed ID: 5073625
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of L-dopa on mental functions in parkinsonism].
    Violon A; Peypers J; Rappel M
    Acta Psychiatr Belg; 1972 Mar; 72(2):168-84. PubMed ID: 5056014
    [No Abstract]   [Full Text] [Related]  

  • 14. [General intelligence of patients with parkinsonism during L-dopa medication (author's transl)].
    Jacobi P; Fischer PA; Schneider E
    Arch Psychiatr Nervenkr (1970); 1974; 218(2):125-40. PubMed ID: 4817897
    [No Abstract]   [Full Text] [Related]  

  • 15. Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1973 Oct; 29(4):493-5. PubMed ID: 4148857
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 17. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.
    Sirtori CR; Bolme P; Azarnoff DL
    N Engl J Med; 1972 Oct; 287(15):729-33. PubMed ID: 5056733
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa.
    Boyd AE; Lebovitz HE; Feldman JM
    J Clin Endocrinol Metab; 1971 Nov; 33(5):829-37. PubMed ID: 5125386
    [No Abstract]   [Full Text] [Related]  

  • 19. L-dopa effects on motor and "central programming" deficits in Parkinsonism.
    Horne DJ
    Psychopharmacologia; 1974 Apr; 36(2):175-80. PubMed ID: 4407693
    [No Abstract]   [Full Text] [Related]  

  • 20. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.